Biocryst Pharmaceuticals Inc (BCRX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Biocryst Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Biocryst Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Biocryst Pharmaceuticals Inc recorded a cumulative net loss of $-385 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -77.51%.
However, within the Healthcare sector 683 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 82 to 4246.
Recent advancements in the field of hereditary angioedema (HAE) prophylaxis have emerged, underscoring the critical need for safer, more effective treatment options for patients affected by this condition. BioCryst Pharmaceuticals, Inc. has made significant strides in this regard with its novel oral therapy, ORLADEYO (berotralstat). The company has announced compelling data from the APeX-P trial that reinforce the efficacy of ORLADEYO in pediatric patients aged 2 to less than 12 years who suffer from HAE.The APeX-P trial yielded positive results, demonstrating the potential of ORLADEYO as a once-daily prophylactic treatment, providing an innovative approach to managing HAE attacks in younger patients. This trial is particularly noteworthy as it focuses on a demographic often underrepresented in clinical research and addresses an urgent medical need. With pediatric patients frequently facing a higher susceptibility to HAE episodes, the availability of ORLADEYO could significantly improve their quality of life and provide peace of mind for families managing this chronic condition.
Title : Unlocking Hope: BioCryst Pharmaceuticals’ Groundbreaking Step Towards Treating Netherton Syndrome with BCX17725 :In the realm of rare genetic disorders, Netherton syndrome looms with its complex tapestry of symptoms, including severe skin manifestations and associated complications that can profoundly affect a patient s quality of life. As the field of biopharmaceuticals continues to unravel new therapeutic avenues, BioCryst Pharmaceuticals Inc. has embarked on a pioneering journey. The company has recently commenced enrollment in a Phase 1 clinical trial for BCX17725, a novel inhibitor targeting the stenotic enzyme KLK5, marking their first protein therapeutic to move into clinical exploration.The significance of this trial extends far beyond mere numbers; it embodies hope for a community long shrouded in uncertainty and struggle. Netherton syndrome, usually linked to mutations in the SPINK5 gene leading to dysregulation in skin barrier function, can manifest in myriad ways, from atopic dermatitis to significant inflammatory responses. The urgency for innovative treatments cannot be overstated, given that effective management strategies have remained scarce.
In a significant stride towards medical breakthroughs, renowned pharmaceutical company BioCryst Pharmaceuticals recently announced its preliminary full-year net revenue for 2023, hitting an impressive milestone of $325 million. The remarkable 29 percent year-on-year growth recorded by their flagship product, ORLADEYO (berotralstat), showcases BioCryst s unwavering commitment to revolutionizing the treatment of rare diseases. With this extraordinary achievement, the company also provides a glimpse into its 2024 guidance and an accelerated path to profitability. ORLADEYO s Stellar Performance: ORLADEYO, an oral therapy designed to prevent hereditary angioedema (HAE) attacks, has carved out a niche for itself in the pharmaceutical realm. Catering to a previously unmet medical need, it has garnered substantial recognition and achieved a stellar net revenue of $325 million in 2023. This monumental fiscal success is not only a testament to BioCryst s unwavering dedication but also a testament to the drug s efficacy in transforming the lives of HAE patients worldwide.
Comment on BCRX's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 45.86 % compared to prior year, due to annual net income growth of % to $263.86 million, while value of Biocryst Pharmaceuticals Inc 's overall assets grew just by 16.92 % to $575.32 million, compared to $575.32 a year before.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
